verapamil has been researched along with Death, Sudden, Cardiac in 28 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Death, Sudden, Cardiac: Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (50.00) | 18.2507 |
| 2000's | 11 (39.29) | 29.6817 |
| 2010's | 3 (10.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bobenko, AI | 1 |
| Heller, S | 1 |
| Schmitt, N | 1 |
| Cherdtrakulkiat, R | 1 |
| Lawung, R | 1 |
| Nabu, S | 1 |
| Tantimavanich, S | 1 |
| Sinthupoom, N | 1 |
| Prachayasittikul, S | 1 |
| Prachayasittikul, V | 1 |
| Zhang, B | 1 |
| Wu, C | 1 |
| Zhang, Z | 2 |
| Yan, K | 1 |
| Li, C | 2 |
| Li, Y | 4 |
| Li, L | 3 |
| Zheng, C | 1 |
| Xiao, Y | 1 |
| He, D | 1 |
| Zhao, F | 1 |
| Su, JF | 1 |
| Lun, SM | 1 |
| Hou, YJ | 1 |
| Duan, LJ | 1 |
| Wang, NC | 1 |
| Shen, FF | 1 |
| Zhang, YW | 1 |
| Gao, ZW | 1 |
| Li, J | 5 |
| Du, XJ | 1 |
| Zhou, FY | 1 |
| Yin, Z | 1 |
| Zhu, J | 2 |
| Yan, D | 1 |
| Lou, H | 1 |
| Yu, H | 1 |
| Feng, C | 1 |
| Wang, Z | 1 |
| Wang, Y | 4 |
| Hu, X | 1 |
| Li, Z | 2 |
| Shen, Y | 1 |
| Hu, D | 1 |
| Chen, H | 1 |
| Wu, X | 1 |
| Duan, Y | 1 |
| Zhi, D | 1 |
| Zou, M | 2 |
| Zhao, Z | 1 |
| Zhang, X | 2 |
| Yang, X | 2 |
| Zhang, J | 3 |
| Wang, H | 1 |
| Popović, KJ | 1 |
| Popović, DJ | 1 |
| Miljković, D | 1 |
| Lalošević, D | 1 |
| Čapo, I | 1 |
| Popović, JK | 1 |
| Liu, M | 1 |
| Song, H | 2 |
| Xing, Z | 1 |
| Lu, G | 1 |
| Chen, D | 1 |
| Valentini, AM | 1 |
| Di Pinto, F | 1 |
| Coletta, S | 1 |
| Guerra, V | 1 |
| Armentano, R | 1 |
| Caruso, ML | 1 |
| Gong, J | 1 |
| Wang, N | 1 |
| Bian, L | 1 |
| Wang, M | 1 |
| Ye, M | 1 |
| Wen, N | 1 |
| Fu, M | 1 |
| Fan, W | 2 |
| Meng, Y | 1 |
| Dong, G | 1 |
| Lin, XH | 1 |
| Liu, HH | 1 |
| Gao, DM | 1 |
| Cui, JF | 1 |
| Ren, ZG | 1 |
| Chen, RX | 1 |
| Önal, B | 1 |
| Özen, D | 1 |
| Demir, B | 1 |
| Akkan, AG | 1 |
| Özyazgan, S | 1 |
| Payette, G | 1 |
| Geoffroy, V | 1 |
| Martineau, C | 1 |
| Villemur, R | 1 |
| Jameel, T | 1 |
| Baig, M | 1 |
| Gazzaz, ZJ | 1 |
| Tashkandi, JM | 1 |
| Al Alhareth, NS | 1 |
| Khan, SA | 1 |
| Butt, NS | 1 |
| Wang, J | 2 |
| Geng, Y | 1 |
| Zhang, Y | 3 |
| Wang, X | 2 |
| Liu, J | 2 |
| Basit, A | 1 |
| Miao, T | 1 |
| Liu, W | 1 |
| Jiang, W | 1 |
| Yu, ZY | 1 |
| Wu, L | 2 |
| Qu, B | 1 |
| Sun, JX | 1 |
| Cai, AL | 1 |
| Xie, LM | 1 |
| Groeneveld, J | 1 |
| Ho, SL | 1 |
| Mackensen, A | 1 |
| Mohtadi, M | 1 |
| Laepple, T | 1 |
| Genovesi, S | 1 |
| Nava, E | 1 |
| Bartolucci, C | 1 |
| Severi, S | 1 |
| Vincenti, A | 1 |
| Contaldo, G | 1 |
| Bigatti, G | 1 |
| Ciurlino, D | 1 |
| Bertoli, SV | 1 |
| Slovak, JE | 1 |
| Hwang, JK | 1 |
| Rivera, SM | 1 |
| Villarino, NF | 1 |
| Li, S | 1 |
| Cao, G | 1 |
| Ling, M | 1 |
| Ji, J | 1 |
| Zhao, D | 1 |
| Sha, Y | 1 |
| Gao, X | 1 |
| Liang, C | 2 |
| Guo, Q | 1 |
| Zhou, C | 1 |
| Ma, Z | 1 |
| Xu, J | 1 |
| Wang, C | 1 |
| Zhao, W | 1 |
| Xia, X | 1 |
| Jiang, Y | 1 |
| Peng, J | 1 |
| Jia, Z | 1 |
| Li, F | 1 |
| Chen, X | 2 |
| Mo, J | 1 |
| Zhang, S | 2 |
| Li, X | 1 |
| Huang, T | 1 |
| Zhu, Q | 1 |
| Wang, S | 1 |
| Ge, RS | 1 |
| Fortunato, G | 1 |
| Lin, J | 2 |
| Agarwal, PK | 1 |
| Kohen, A | 1 |
| Singh, P | 1 |
| Cheatum, CM | 1 |
| Zhu, D | 1 |
| Hayman, A | 1 |
| Kebede, B | 1 |
| Stewart, I | 1 |
| Chen, G | 1 |
| Frew, R | 1 |
| Guo, X | 1 |
| Gong, Q | 1 |
| Borowiec, J | 1 |
| Han, S | 1 |
| Zhang, M | 1 |
| Willis, M | 1 |
| Kreouzis, T | 1 |
| Yu, K | 1 |
| Chirvony, VS | 1 |
| Sekerbayev, KS | 1 |
| Pérez-Del-Rey, D | 1 |
| Martínez-Pastor, JP | 1 |
| Palazon, F | 1 |
| Boix, PP | 1 |
| Taurbayev, TI | 1 |
| Sessolo, M | 1 |
| Bolink, HJ | 1 |
| Lu, M | 1 |
| Lan, Y | 1 |
| Xiao, J | 1 |
| Song, M | 1 |
| Chen, C | 1 |
| Huang, Q | 1 |
| Cao, Y | 1 |
| Ho, CT | 1 |
| Qi, B | 1 |
| Wang, Q | 1 |
| Zhang, W | 1 |
| Fang, L | 1 |
| Xie, CL | 1 |
| Chen, R | 1 |
| Yang, S | 1 |
| Xia, JM | 1 |
| Zhang, GY | 1 |
| Chen, CH | 1 |
| Yang, XW | 1 |
| Domenech-Ximenos, B | 1 |
| Garza, MS | 1 |
| Prat-González, S | 1 |
| Sepúlveda-Martínez, Á | 1 |
| Crispi, F | 1 |
| Perea, RJ | 1 |
| Garcia-Alvarez, A | 1 |
| Sitges, M | 1 |
| Kalumpha, M | 1 |
| Guyo, U | 1 |
| Zinyama, NP | 1 |
| Vakira, FM | 1 |
| Nyamunda, BC | 1 |
| Varga, M | 1 |
| Drácz, L | 1 |
| Kolbenheyer, E | 1 |
| Varga, F | 1 |
| Patai, ÁV | 1 |
| Solymosi, N | 1 |
| Patai, Á | 1 |
| Kiss, J | 1 |
| Gaál, V | 1 |
| Nyul, Z | 1 |
| Mosdósi, B | 1 |
| Valdez, M | 1 |
| Moosavi, L | 1 |
| Heidari, A | 1 |
| Novakovic-Agopian, T | 1 |
| Kornblith, E | 1 |
| Abrams, G | 1 |
| McQuaid, JR | 1 |
| Posecion, L | 1 |
| Burciaga, J | 1 |
| D'Esposito, M | 1 |
| Chen, AJW | 1 |
| Samy El Gendy, NM | 1 |
| Wesolowska, P | 1 |
| Georg, D | 1 |
| Lechner, W | 1 |
| Kazantsev, P | 1 |
| Bokulic, T | 1 |
| Tedgren, AC | 1 |
| Adolfsson, E | 1 |
| Campos, AM | 1 |
| Alves, VGL | 1 |
| Suming, L | 1 |
| Hao, W | 1 |
| Ekendahl, D | 1 |
| Koniarova, I | 1 |
| Bulski, W | 1 |
| Chelminski, K | 1 |
| Samper, JLA | 1 |
| Vinatha, SP | 1 |
| Rakshit, S | 1 |
| Siri, S | 1 |
| Tomsejm, M | 1 |
| Tenhunen, M | 1 |
| Povall, J | 1 |
| Kry, SF | 1 |
| Followill, DS | 1 |
| Thwaites, DI | 1 |
| Izewska, J | 1 |
| Kang, JH | 1 |
| Yoon, Y | 1 |
| Song, J | 1 |
| Van de Winckel, A | 1 |
| Gauthier, L | 1 |
| Chao, CT | 1 |
| Lee, YH | 1 |
| Li, CM | 1 |
| Han, DS | 1 |
| Huang, JW | 1 |
| Huang, KC | 1 |
| Ni, L | 1 |
| Güttinger, R | 1 |
| Triana, CA | 1 |
| Spingler, B | 1 |
| Baldridge, KK | 1 |
| Patzke, GR | 1 |
| Shen, X | 1 |
| Wang, B | 1 |
| Xie, S | 1 |
| Deng, W | 1 |
| Wu, D | 1 |
| Zhang, Q | 1 |
| Voskamp, BJ | 1 |
| Peelen, MJCS | 1 |
| Ravelli, ACJ | 1 |
| van der Lee, R | 1 |
| Mol, BWJ | 1 |
| Pajkrt, E | 1 |
| Ganzevoort, W | 1 |
| Kazemier, BM | 1 |
| Tibrewala, R | 1 |
| Bahroos, E | 1 |
| Mehrabian, H | 1 |
| Foreman, SC | 1 |
| Link, TM | 1 |
| Pedoia, V | 1 |
| Majumdar, S | 1 |
| Jablonski, CL | 1 |
| Leonard, C | 1 |
| Salo, P | 1 |
| Krawetz, RJ | 1 |
| Yoon, N | 1 |
| Hong, SN | 1 |
| Cho, JG | 1 |
| Jeong, HK | 1 |
| Lee, KH | 1 |
| Park, HW | 1 |
| Barman, S | 1 |
| Konai, MM | 1 |
| Samaddar, S | 1 |
| Haldar, J | 1 |
| Mohamed, HSH | 1 |
| Li, CF | 1 |
| Hu, ZY | 1 |
| Deng, Z | 1 |
| Chen, LH | 1 |
| Su, BL | 1 |
| Chu, K | 1 |
| Liu, YP | 1 |
| Li, YB | 1 |
| Zhang, H | 1 |
| Xu, C | 1 |
| Zou, Z | 1 |
| Wu, Z | 1 |
| Xia, Y | 1 |
| Zhao, P | 1 |
| Wang, HT | 1 |
| de Biase, S | 1 |
| Pellitteri, G | 1 |
| Gigli, GL | 1 |
| Valente, M | 1 |
| Gibelin, P | 1 |
| Pott, C | 1 |
| Dechering, DG | 1 |
| Reinke, F | 1 |
| Muszynski, A | 1 |
| Zellerhoff, S | 1 |
| Bittner, A | 1 |
| Köbe, J | 1 |
| Wasmer, K | 1 |
| Schulze-Bahr, E | 1 |
| Mönnig, G | 1 |
| Kotthoff, S | 1 |
| Eckardt, L | 1 |
| Prinz, C | 1 |
| Farr, M | 1 |
| Hering, D | 1 |
| Horstkotte, D | 1 |
| Faber, L | 1 |
| Sumitomo, N | 1 |
| Harada, K | 1 |
| Nagashima, M | 1 |
| Yasuda, T | 1 |
| Nakamura, Y | 1 |
| Aragaki, Y | 1 |
| Saito, A | 1 |
| Kurosaki, K | 1 |
| Jouo, K | 1 |
| Koujiro, M | 1 |
| Konishi, S | 1 |
| Matsuoka, S | 1 |
| Oono, T | 1 |
| Hayakawa, S | 1 |
| Miura, M | 1 |
| Ushinohama, H | 1 |
| Shibata, T | 1 |
| Niimura, I | 1 |
| Favale, S | 1 |
| Pappone, C | 1 |
| Nacci, F | 1 |
| Fino, F | 1 |
| Resta, F | 1 |
| Dicandia, CD | 1 |
| Maron, BJ | 3 |
| McKenna, WJ | 2 |
| Danielson, GK | 1 |
| Kappenberger, LJ | 1 |
| Kuhn, HJ | 1 |
| Seidman, CE | 2 |
| Shah, PM | 1 |
| Spencer, WH | 1 |
| Spirito, P | 2 |
| Ten Cate, FJ | 1 |
| Wigle, ED | 1 |
| Ray, WA | 1 |
| Murray, KT | 1 |
| Meredith, S | 1 |
| Narasimhulu, SS | 1 |
| Hall, K | 1 |
| Stein, CM | 1 |
| Fehri, W | 1 |
| Abdessalem, S | 1 |
| Smiri, Z | 1 |
| Mhenni, H | 1 |
| Barakett, N | 1 |
| Rahal, N | 1 |
| Haouala, H | 1 |
| Hjemdahl, P | 2 |
| Eriksson, SV | 1 |
| Held, C | 2 |
| Forslund, L | 2 |
| Näsman, P | 1 |
| Rehnqvist, N | 2 |
| Melacini, P | 1 |
| Bobbo, F | 1 |
| Basso, C | 1 |
| Tokajuk, B | 1 |
| Zucchetto, M | 1 |
| Thiene, G | 2 |
| Iliceto, S | 1 |
| Hansen, JF | 3 |
| Suner, S | 1 |
| Simon, HK | 1 |
| Feit, LR | 1 |
| Linakis, JG | 1 |
| Leenhardt, A | 1 |
| Glaser, E | 1 |
| Burguera, M | 1 |
| Nürnberg, M | 1 |
| Maison-Blanche, P | 1 |
| Coumel, P | 1 |
| Andersen, L | 1 |
| Sigurd, B | 1 |
| Hansen, J | 1 |
| Whitehurst, VE | 1 |
| Joseph, X | 1 |
| Vick, JA | 1 |
| Alleva, FR | 1 |
| Balazs, T | 1 |
| Timour, Q | 1 |
| Freysz, M | 1 |
| Aupetit, JF | 1 |
| Loufoua, J | 1 |
| Frassati, D | 1 |
| Faucon, G | 1 |
| Burnett, JW | 1 |
| Ruan, Y | 1 |
| Wang, L | 1 |
| Dumestre-Toulet, V | 1 |
| Cirimele, V | 1 |
| Gromb, S | 1 |
| Belooussoff, T | 1 |
| Lavault, D | 1 |
| Ludes, B | 1 |
| Kintz, P | 1 |
| Björkander, I | 1 |
| Ericson, M | 1 |
| Kahan, T | 1 |
| Sung, RJ | 1 |
| Huycke, EC | 1 |
| Ometto, R | 1 |
| Corrado, D | 1 |
| Vincenzi, M | 1 |
| Rossi, L | 1 |
| Mazur, NA | 1 |
| Vasil'eva, NN | 1 |
| Pavlova, TS | 1 |
| Kul'ginskaia, IV | 1 |
| Zhdanova, SM | 1 |
| Tworek, DA | 1 |
| Nazari, J | 1 |
| Ezri, M | 1 |
| Bauman, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy[NCT04133532] | Phase 4 | 22 participants (Actual) | Interventional | 2020-03-05 | Completed | ||
| Correlation Between Myocardial Deformation and Coronary Artery Morphology in Patients With Hypertrophic Cardiomyopathy and Analysis of Genetic Factors：A Prospective, Single-center, Case-control Study[NCT04830787] | 302 participants (Actual) | Observational | 2017-12-01 | Completed | |||
| Comparison of Two Macrolides, Azithromycin and Erythromycin, for Symptomatic Treatment of Gastroparesis[NCT01323582] | Phase 2 | 26 participants (Actual) | Interventional | 2009-02-28 | Terminated (stopped due to Original investigator left this institution, replacement investigator retired.) | ||
| Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome[NCT01607073] | Phase 2 | 2 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients will be given a standardized meal enriched with a labeled material and the breath samples are then collected and analyzed. The estimated time to reaching 50% of the accumulated contents is recorded. (NCT01323582)
Timeframe: at baseline before initiation of the treatment and after completion of each treatment period.
| Intervention | minutes (Mean) |
|---|---|
| Azithromycin | -15.0 |
Patients will be given a standardized meal enriched with a labeled material and the breath samples are then collected and analyzed. The estimated time to reaching 50% of the accumulated contents is recorded. (NCT01323582)
Timeframe: Baseline and end of treatment period
| Intervention | Minutes (Mean) |
|---|---|
| Erythromycin | -11.8 |
"This is a Validated instrument for measuring symptom severity in patients with gastroparesis. This scoring is based on a Likert Scale from (0-5) with zero being no symptom and five being very severe symptoms on 9 subscales, making the overall score range from 0-45. The higher the score, the more severe patient's symptoms are. The scale is reported in the references.~This is a calculation taken with GCSI score at end of treatment minus baseline. Negative value reflects this change." (NCT01323582)
Timeframe: Baseline and end of treatment period
| Intervention | units on a scale (Median) |
|---|---|
| Azithromycin | -6.40 |
"This is a Validated instrument for measuring symptom severity in patients with gastroparesis. This scoring is based on a Likert Scale from (0-5) with zero being no symptoms and five being very severe symptoms on 9 subscales, making the overall score range from 0-45. The higher the score, the more severe patient's symptoms.~Reference for GCSI: Revicki DA, REntz AM, Dubois D, et al. Development and validation of a patient-assessed gastroparesis symptoms severity measure: the Gastroparesis Cardinal Symptom Index. Ailment Pharm Ther 2003; 18: 141:50.~Because the difference is RX-B -RX A in one group and RX A -RX B in the other, the difference between these two estimates twice the effect size. Hence the Half is applied, as is standard in the two sample method for crossover studies." (NCT01323582)
Timeframe: Weeks 4 and 11 (end of periods)
| Intervention | units on a scale (Mean) |
|---|---|
| Erythromycin First Then Azithromycin | -1.6 |
| Azithromycin Then Erythromycin | -2.9 |
"This is a Validated instrument for measuring symptom severity in patients with gastroparesis. This scoring is based on a Likert Scale from (0-5) with zero being no symptom and five being very severe symptoms on 9 subscales, making the overall score range from 0-45. The higher the score, the more severe patient's symptoms are. The scale is reported in the references. The change was calculated by measuring the end of treatment minus baseline GCSI score.~Negative value reflects this change." (NCT01323582)
Timeframe: Baseline and end of treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Erythromycin | -5.32 |
"Nepean Dyspepsia Index (NDI) is a measure of symptom status and quality of life in functional dyspepsia. This scale is scored using each subscale (Tension, interference with daily activities), Eating/drinking, Knowledge/control, work/study) and adding up the items for each of the five subscale score (2-10). Total score range would be 10-50).~For the NDI, a lower number is better meaning the symptom is not effecting quality of life and a higher score closer to 50 is worse meaning it is effecting patients quality of life.~Reference: Talley NJ, Verlinden M, Jones M. Quality of life in functional dyspepsia: responsiveness of the Nepean Dyspepsia Index and developement of a new 10-iten short form. Aliment Pharmacol Ther 2001: 15: 207-216.~Because the difference is RX-B -RX A in one group and RX A -RX B in the other, the difference between these two estimates twice the effect size. Hence the Half is applied, as is standard in the two sample method for crossover studies." (NCT01323582)
Timeframe: Weeks 4 and 11 (end of periods)
| Intervention | units on a scale (Median) |
|---|---|
| Erythromycin First Then Azithromycin | 1.65 |
| Azithromycin Then Erythromycin | 1.30 |
Patients will be given a standardized meal enriched with a labeled material and the breath samples are then collected and analyzed. The estimated time to empty 50% (t 1/2) of the accumulated contents is recorded. Because the difference is RX-B -RX A in one group and RX A -RX B in the other, the difference between these two estimates twice the effect size. Hence the Half is applied, as is standard in the two sample method for crossover studies. (NCT01323582)
Timeframe: Weeks 4 and 11 (end of periods)
| Intervention | Minutes (Mean) |
|---|---|
| Erythromycin First Then Azithromycin | -1.6 |
| Azithromycin Then Erythromycin | -5.2 |
This is defined as the time from ingestion of the meal to the beginning of the emptying process in minutes. Because the difference is RX-B -RX A in one group and RX A -RX B in the other, the difference between these two estimates twice the effect size. Hence the Half is applied, as is standard in the two sample method for crossover studies. (NCT01323582)
Timeframe: Weeks 4 and 11 (end of periods)
| Intervention | Minutes (Mean) |
|---|---|
| Erythromycin First Then Azithromycin | -1.71 |
| Azithromycin Then Erythromycin | -0.22 |
The secondary outcome measure is the change in number of absence seizures from Week 8 (Baseline) to Week 12 (NCT01607073)
Timeframe: Week 8 to Week 12
| Intervention | Abscence seizures (Number) |
|---|---|
| Week 8 Baseline | 165 |
| Week 12 Verapamil 4mg/kg/Day | 101 |
The primary study endpoint is the change in number of seizures from baseline. Since we only had one participant finish the study, the endpoint was changed to Week 12 visit. Participants were on verapamil for 4 weeks at Week 12. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | General tonic-clonic seizures (Number) |
|---|---|
| Week 8 Baseline | 39 |
| Week 12 Verapamil 4mg/kg/Day | 14 |
The secondary outcome is the change in number of myoclonic seizures between baseline Week 8 visit and Week 12 visit. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | Myoclonic seizures (Number) |
|---|---|
| Week 8 Baseline | 116 |
| Week 12 Verapamil 4mg/kg/Day | 175 |
8 reviews available for verapamil and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P | 2019 |
Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Calcium Channel Blockers; Child; Death, Sudden, | 2011 |
The diagnosis and treatment of hypertrophic cardiomyopathy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Cardiac Surgical Procedures; Cardiomyopathy, Hypertr | 2011 |
American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European S
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Pacing, Artificial; | 2003 |
American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European S
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Pacing, Artificial; | 2003 |
American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European S
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Pacing, Artificial; | 2003 |
American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European S
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Pacing, Artificial; | 2003 |
The management of hypertrophic cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Cardiac Pacing, Artificial; Cardiomyopathy, Hypert | 1997 |
Ventricular arrhythmias in the absence of organic heart disease.
Topics: Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Death, Sudden, Cardiac; Diagnosis, Computer-As | 1992 |
Treatment with verapamil during and after an acute myocardial infarction: a review based on the Danish Verapamil Infarction Trials I and II. The Danish Study Group on Verapamil in Myocardial Infarction.
Topics: Arrhythmias, Cardiac; Blood Pressure; Death, Sudden, Cardiac; Denmark; Double-Blind Method; Female; | 1991 |
Interference by antiarrhythmic agents with function of electrical cardiac devices.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Death, Sudden, Cardiac; Digoxin; Drug Interactions; Ele | 1992 |
6 trials available for verapamil and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS).
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Death, Sudden, Cardiac; Diab | 2006 |
Postinfarct treatment with verapamil. Effect of verapamil in patients with hypertension.
Topics: Cerebrovascular Disorders; Death, Sudden, Cardiac; Denmark; Double-Blind Method; Follow-Up Studies; | 1993 |
Verapamil and circadian variation of sudden cardiac death.
Topics: Calcium Channel Blockers; Circadian Rhythm; Death, Sudden, Cardiac; Double-Blind Method; Humans; Myo | 1996 |
Prognostic implications of autonomic function assessed by analyses of catecholamines and heart rate variability in stable angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Anti-Arrhythmia Agents; Autonomic Nervous System Diseases; Biomarkers; | 2002 |
[Calcium antagonists. The prevention of a recurrent myocardial infarct and sudden death].
Topics: Calcium Channel Blockers; Death, Sudden, Cardiac; Drug Therapy, Combination; Electrocardiography, Am | 1992 |
Treatment with verapamil during and after an acute myocardial infarction: a review based on the Danish Verapamil Infarction Trials I and II. The Danish Study Group on Verapamil in Myocardial Infarction.
Topics: Arrhythmias, Cardiac; Blood Pressure; Death, Sudden, Cardiac; Denmark; Double-Blind Method; Female; | 1991 |
15 other studies available for verapamil and Death, Sudden, Cardiac
| Article | Year |
|---|---|
[Drug treatment for hypertrophic cardiomyopathy].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cardiomyop | 2009 |
Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Catecholamines; Catheter Abl | 2003 |
Sudden death due to atrial fibrillation in hypertrophic cardiomyopathy: a predictable event in a young patient.
Topics: Adult; Amiodarone; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardiac; Defibr | 2003 |
Oral erythromycin and the risk of sudden death from cardiac causes.
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases | 2004 |
[Short coupled variant of torsade de pointes: our experience and review of the literature].
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implant | 2004 |
Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyop | 2007 |
Child with idiopathic ventricular tachycardia of prolonged duration.
Topics: Child, Preschool; Death, Sudden, Cardiac; Electric Countershock; Electrocardiography; Humans; Male; | 1995 |
Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias.
Topics: Adult; Cardiac Pacing, Artificial; Death, Sudden, Cardiac; Defibrillators, Implantable; Electrocardi | 1994 |
Verapamil prevents sudden death in patients with increased heart size after an acute myocardial infarction.
Topics: Cardiomegaly; Clinical Trials as Topic; Death, Sudden, Cardiac; Female; Humans; Male; Myocardial Inf | 1993 |
Reversal of acute theophylline toxicity by calcium channel blockers in dogs and rats.
Topics: Animals; Arrhythmias, Cardiac; Blood Pressure; Bronchodilator Agents; Calcium; Calcium Channel Block | 1996 |
[Value of calcium channel blockers in the prevention of ventricular fibrillation of ischemic etiology: experimental arguments].
Topics: Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Death, Sudden, Cardiac; Hemodynamics; Hum | 1996 |
The case for the use of verapamil in alarming Chironex stings.
Topics: Animals; Anti-Arrhythmia Agents; Antivenins; Bites and Stings; Calcium Channel Blockers; Cnidarian V | 1998 |
Short-coupled variant of torsade de pointes.
Topics: Adult; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Electrocardiography; Female; Follow-Up Studie | 2001 |
Last performance with VIAGRA: post-mortem identification of sildenafil and its metabolites in biological specimens including hair sample.
Topics: Adult; Autopsy; Bromazepam; Cause of Death; Chromatography, Liquid; Death, Sudden, Cardiac; Drug Int | 2002 |
Enhanced A-V nodal conduction (Lown-Ganong-Levine syndrome) by congenitally hypoplastic A-V node.
Topics: Adult; Atrioventricular Node; Cardiac Pacing, Artificial; Death, Sudden, Cardiac; Electrocardiograph | 1992 |